I. COMMENCED TRADING IN JUNE

INITIAL OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


There were no initial public offerings in June.

Total: $0M

Number of IPOs in June: 0

Average value of June IPOs: $0M

Number of IPOs for 2001: 8

Total raised in IPOs in 2001: $268.55M

Average value of IPOs in 2001: $33.57M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


Arena
Pharmaceuticals
Inc.
(ARNA)1

6/5

6/22

4S

$27.50

26.7

Thomas Weisel Partners LLC;
Dain Rauscher Wessels;
ABN Amro Rothschild LLC
Lazard Freres & Co. LLC

$110

$103.5

CV Therapeutics
Inc.
(CVTX)2

1/4

6/7

2.02S

$49.50

21.8

SG Cowen Securities Corp.

$100

$95.7

InterMune
Inc.
(ITMN)3

6/5;
6/15

6/29

3.75S

$32

27.7

Lehman
Brothers Inc.;
Bank of America Securities Inc.;
Robertson Stephens Inc.;
UBS Warburg LLC

$250

$238

KS Biomedix
Holdings plc
(UK; LSE:KSB)4

6/27**

6/27**

6S

#3.15
(US
$4.46)

N/A

WestLB Panmure

#19
(US$27)

N/A

Scios Inc.
(SCIO)5

1/19

6/22

5.75S

$21

44.62

JP Morgan Securities Inc.;
Lehman
Brothers Inc.;
SG Cowen
Securities Corp.

$120.75

$114

Transkaryotic
Therapies Inc.
(TKTX)6

12/13

6/26

3.1S

$28.50

22.8

SG Cowen Securities

$88.4

$83.6

XOMA Ltd.
(XOMA)7

11/17

6/26

3S

$15

66.1

U.S. Bancorp Piper Jaffray;
CIBC World
Markets;
Adams,
Harkness
& Hill Inc.;
Arnold & S. Bleichroeder Inc.

$45

$43.3

Notes:

** Denotes the date the item ran in BioWorld International.

1. Arena sold 4M shares and selling stockholders sold another 1M shares. The underwriters have an overallotment option for 750,000 more shares.

2. CV Therapeutics raised $100M through a public offering of 2.02M shares.

3. Intermune's offering consisted of 3.75M shares sold at $32 a share, raising $120M, and the sale of 5.75% convertible subordinated notes for $130M. The offering includes an overallotment option for 545,896 shares and $19.5M principal amount of convertible subordinated notes.

4. KS Biomedix raised #19 with the placement of 6M shares.

5. Scios' offering includes the exercise of the overallotment option for 750,000 shares.

6. Transkaryotic Therapies raised $88M in a public offering of 3.1M shares at $28.50 each. The underwriter has an option to purchase up to 465,000 additional shares to cover overallotments.

7. XOMA sold 3M shares for net proceeds of $43.3M.

Total: $741.15M

Number of follow-on offerings in June: 7

Average value of June follow-ons: $105.88M

Number of follow-on offerings in 2001: 19

Total raised in follow-ons in 2001: $1,780.25M

Average value of follow-ons in 2001: $93.7M

II. FILED AND PENDING

INITIAL OFFERINGS

Company
(Symbol/
Proposed Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


Acadia
Pharmaceuticals
Inc.
(ACAD)1

12/21

5S

$13-15

15.8

Robertson Stephens Inc. (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

APBiotech
(APBI; unit of
Nycomed
Amersham plc)2

10/3

18.2

$15-17

208.6

Morgan Stanley Dean Witter (co-lead); Goldman, Sachs & Co. (co-lead); Chase H&Q;
Salomon Smith Barney

$291.2

BioNumerik
(BNPI)3

3/2

N/A

N/A

N/A

Morgan Stanley Dean Witter;
UBS Warburg LLC;
SG Cowen Securities
Corp.

$50

CombiMatrix
Corp.
(CLMX)4

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead); J.P. Morgan
& Co. (co-lead)

$100

diaDexus Inc.
(DDXS)5

11/20

7S

$12-14

31.1

Lehman Brothers Inc.;
CIBC World Markets Corp.;
Robertson Stephens Inc.;
Fidelity Capital Markets

$91

DNA Sciences
Inc.
(DNAS)6

1/5

N/A

N/A

N/A

Lehman Brothers Inc.;
CIBC World Markets
Corp.; Dain Rauscher
Wessels Inc.

$125

Ethypharm
(France)7

6/18

10.94S

$8.95-
10.40

N/A

Schroder Salomon Smith Barney; ABN AMRO
Rothschild; Robertson
Stephens International;
Banque Nomura France

EUR160
(US$137)

Meristem
Therapeutics
(France)8

6/27**

2.275S

EUR22-
25.50
(US
$18.90-
21.90)

N/A

Credit Lyonnais;
WestLB Panmure

EUR54 (US$46)

NetGenics Inc.
(NTGC)9

3/13/00

5.5S

$11-13

23.5

Chase H&Q;
UBS Warburg LLC

$66

Ribapharm Inc.
(RIBA)10

5/15

18S

$13-15

N/A

UBS Warburg LLC;
CIBC World Markets
Corp.

$252

Senomyx Inc.
(SNMX)11

2/21

N/A

N/A

17.4

Deutsche Banc Alex. Brown;
Bear, Stearns & Co. Inc.;
CIBC World Markets Corp.

$80

Xcyte Therapies
Inc.
(XCYT)12

12/22

N/A

N/A

N/A

SG Cowen Securities
Corp. (co-lead); U.S.
Bancorp Piper Jaffray (co-lead); Dain Rauscher
Inc.; First Security Van
Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Company
(Symbol/
Proposed Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


Aastrom
Biosciences Inc.
(ASTM)13

12/7

7.7S

$0.96

33.84

N/A

$7.392

Alexion
Pharmaceuticals
Inc.
(ALXN)14

10/6

N/A

N/A

N/A

N/A

$300

Alteon Inc.
(AMEX:ALT)15

3/5

N/A

N/A

22.5

N/A

$50

Ariad
Pharmaceuticals
Inc.
(ARIA)16

6/22

4.5S

$4.79

34.6

N/A

$21.6

Atrix
Laboratories
Inc.
(ATRX)17

2/15

4S

$25

14.9

N/A

$100

Cell Pathways
Inc.
(CLPA)18

2/7

N/A

N/A

N/A

N/A

$25

Charles River
Laboratories
International
Inc.
(NYSE:
CRL)19

6/27

2S

$31.20

42.1

Credit Suisse First Boston
(co-lead); Lehman Brothers
(co-lead); SG Cowen
Securities; U.S. Bancorp
Piper Jaffray;

$62.4

Chiron Corp.
(CHIR)20

6/7

5.2S

$6.19

190

N/A

$400

ConjuChem
Inc.
(Canada;
TSE:CJC)21

5/30

N/A

N/A

N/A

Yorkton Securities;
BMO Nesbitt Burns Inc.;
HSBC Securities Inc.

N/A

ICOS Corp.
(ICOS)22

6/26

N/A

N/A

53

N/A

$300

InSite Vision
Inc.
(AMEX:
ISV)23

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co.
(placement agent)

$40

Matrix
Pharmaceuticals
Inc.
(MATX)24

5/25

N/A

N/A

26

N/A

$30

Medarex Inc.
(MEDX)25

6/19

N/A

N/A

72.7

Goldman Sachs & Co.;
Credit Suisse First Boston;
JP Morgan; Morgan Stanley Dean Witter; Bear, Stearns & Co. Inc.; Dain Rauscher Wessels

$175

Microcide
Pharmaceuticals
Inc.
(MCDE)26

2/12

N/A

N/A

N/A

N/A

$35

NeoTherapeutics
Inc.
(NEOT)27

1/3

N/A

N/A

17.26

N/A

$50

Vion
Pharmaceuticals
Inc.
(VION)28

4/3

4.7S

$6.75

26.2

N/A

$31.73

III. WITHDRAWN AND POSTPONED

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed/
Date
Pulled

Shares/
Units
(M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


Cerep SA (France;
Nouveau Marche:
CERE)29

6/6
6/27**

0.4-
0.46S

N/A

N/A

BNP Paribas

EUR40
(US$34)

Zentaris AG
(Germany)30

5/23**
6/18

9.5S

EUR11-
14 (US
$9.30-
11.9)

N/A

Dresdner Kleinwort
Wasserstein; HSBC Trinkaus
und Burkhardt; Landesbank
Baden-W|rttemberg

EUR118.8
(US$100.7)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

**Denotes the date the item ran in BioWorld International.

N/A = Not available or reported.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

1. Acadia's underwriters have an overallotment option for 750,000 shares.

2. APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

3. BioNumerik filed for a $50M IPO. The number of shares to be offered, the price range, and the number of shares outstanding were not disclosed.

4. CombiMatrix did not disclose any further details.

5. diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

6. DNA Sciences did not disclose any further details.

7. Ethypharm hopes to raise US$137M through an IPO it launched on the Premier Marche of the Euronext stock exchange in Paris. The underwriters have an overallotment option for an additional 2.13M shares.

8. Meristem expects to raise at least US$46M in an IPO on the Nouveau Marche of the Euronext stock exchange in Paris. The underwriters have an overallotment option for 341,250 shares

9. NetGenics' IPO value, $66M, is based on the sale of 5.5M shares at $12 each, the midpoint of the expected price range. The underwriters have an overallotment option for 825,000 shares.

10. Ribapharm's IPO was originally proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

11. Senomyx did not disclose any further details.

12. Xcyte did not disclose any further details.

13. Aastrom amended its prospectus 12/29 increasing the offering from 6.35M shares to 7.7M shares. The offering value, $7.4M, is based on the proposed maximum aggregate price of $0.96 per share. The company placed 1.18M shares in a private placement in May, raising $1.1M. The company placed 1.89M shares in private placements in June, raising $2.95M.

14. Alexion filed a shelf registration to offer common stock, debt or warrants, up to a value of $300M.

15. Alteon filed a shelf registration statement to sell $50M in shares.

16. Ariad's offering value is based on the proposed maximum offering share price of $4.79.

17. Atrix filed to put 4M shares on the shelf. The value of the proposed offering, $100M, is based on the Feb. 15 closing stock price of $25.

18. Cell Pathways filed a shelf registration for the sale of $25M in common stock.

19. Charles River said the offering of 8M shares includes 2M offered by the company and the rest offered by selling shareholders. The underwriters will have an overallotment option for another 1.2M shares. The offering's value is based on the 6/22 closing stock price of $31.20.

20. Chiron Corp. plans to raise $400M through an offering of 30-year liquid yield option notes that could equate to 5.2M shares.

21. ConjuChem filed a preliminary prospectus for a new issue and secondary offering in Canada. No other information was made available.

22. ICOS filed a shelf registration statement for up to $300M.

23. InSite filed a shelf registration to sell $40M in stock

24. Matrix filed a shelf registration covering up to $30M in securities.

25. Medarex plans to raise $175M through an offering of convertible notes due 2006. The offering will include an overallotment option for $26.25M principal amount of the notes to cover overallotments.

26. Microcide filed a shelf registration for the sale of up to $35M in securities.

27. NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. The company amended its prospectus April 19. The company plans to offer 0.59M shares to Montrose Investments Ltd. and 0.59M shares to Strong River Investments for $6M.

28. Vion filed a shelf registration statement to sell up to 5M shares, but later amended it to sell 4.7M shares. The value, $31.73M, is based on the 5/29 closing stock price of $6.75.

29. Cerep planned to issue between 400,000 and 460,000 new shares to raise about US$34M, but it pulled the offering because of market conditions.

30. Zentaris postponed its IPO until further notice.

No Comments